This is a phase II study to determine the efficacy and safety of tislelizumab when given in
combination with lenvatinib as treatment for patients with the advanced kidney cancer .
Patients will receive treatment with tislelizumab in combination with lenvatinib every 3
weeks unitl tumor progression or serious side effects